Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery

A 58-year-old morbidly obese male (body mass index: 38 kg/m2) with severe haemophilia A underwent total knee replacement surgery. Perioperatively, factor VIII (FVIII) levels were measured daily and maximum a posteriori (MAP) Bayesian estimation was used to calculate the individual pharmacokinetic (PK) parameters and doses required to obtain prescribed FVIII target levels. In the MAP Bayesian procedure, a population PK model was used in which PK parameters were normalised using body weight. In this specific case, ideal body weight was used to scale the PK parameters instead of actual body weight. Except for the preoperative FVIII level, adequate FVIII levels were achieved during the 10-day perioperative period. During follow-up visits, the knee prosthesis was reported to function adequately.

[1]  A. Graham,et al.  Pharmacokinetic analysis of anti‐hemophilic factor in the obese patient , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  J. Garrow,et al.  Quetelet's index (W/H2) as a measure of fatness. , 1985, International journal of obesity.

[3]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Kruip,et al.  Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation , 2016, BMJ Case Reports.

[5]  M. Escobar,et al.  Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis , 2013, Journal of thrombosis and haemostasis : JTH.

[6]  F. Leebeek,et al.  Diagnosis and management of haemophilia , 2012, BMJ : British Medical Journal.

[7]  N. Speybroeck,et al.  Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients , 2013, Haematologica.

[8]  H. C. A. M. Hazendonka,et al.  Setting the stage for individualized therapy in hemophilia : What role can pharmacokinetics play ? , 2018 .

[9]  R. Liesner,et al.  The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation , 2006, British journal of haematology.

[10]  F. Leebeek,et al.  A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients , 2016, Haematologica.

[11]  E. Nielsen,et al.  Real life experiences of a PK dosing study—Challenges and lessons learned. , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  R. Ljung,et al.  Definitions in hemophilia: communication from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[13]  A. Iorio,et al.  Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  C. Hermans,et al.  Continuous infusion of factor VIII concentrates in obese patients with severe haemophilia A: is weight‐based dose‐adjustment required? , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  F. Leebeek,et al.  Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? , 2018, Blood reviews.

[16]  M. McCarron,et al.  Clinical Pharmacy: Case Studies , 1974 .

[17]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.